Structure Therapeutics reports more Phase 2 data for oral GLP-1
结构治疗公司报告其口服GLP-1的更多II期临床数据

Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.
结构治疗公司备受期待的口服GLP-1试验数据已公布，结果显示这款下一代候选药物有望挑战市场现有巨头礼来和诺和诺德。